Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes

B. N. Yamaja Setty1 and Suhita Gayen Betal1

1Marian Anderson Comprehensive Sickle Cell Anemia Care and Research Center, Department of Pediatrics, Division of Research Hematology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

Phosphatidylserine (PS)–positive erythrocytes adhere to endothelium and subendothelial matrix components. While thrombospondin mediates these interactions, it is unknown whether PS–associated erythrocyte-endothelial adhesion occurs in the absence of plasma ligands. Using ionophore-treated PS-expressing control HbAA erythrocytes, we demonstrate that PS-positive erythrocytes adhered to human lung microendothelial cells in the absence of plasma ligands, that this adhesion was enhanced following endothelial activation with IL-1α, TNF-α, LPS, hypoxia, and heme, and that this adhesive interaction was selective to erythrocyte PS. We next explored whether microendothelial cells express an adhesion receptor that recognizes cell surface–expressed PS (PSR) similar to that expressed on activated macrophages. We demonstrate constitutive expression of both PSR mRNA and protein that were up-regulated in a time-dependent manner following endothelial activation. While minimal PSR expression was noted on unstimulated cells, endothelial activation up-regulated PSR surface expression. In antibody-blocking studies, using PS-positive erythrocytes generated either artificially via ionophore treatment of control erythrocytes or from patients with sickle cell disease, we demonstrate that PSR was functional, supporting PS-mediated erythrocyte adhesion to activated endothelium. Our results demonstrate the existence of a novel functional adhesion receptor for PS on the microendothelium that is up-regulated by such pathologically relevant agonists as hypoxia, cytokines, and heme. (Blood. 2008; 111:905-914)

© 2008 by The American Society of Hematology

Introduction

The anionic phospholipid phosphatidylserine (PS), present exclusively in the inner leaflet of the plasma membrane of a normal cell, is externalized following cell activation with both physiologic and pathologic stimuli such as activation of blood platelets resulting from vessel wall injury and cells that are undergoing apoptosis.1,2 PS exposure on the red cell surface occurs in patients with various hemolytic anemias,3-9 activating numerous pathobiologic processes, of which one is red cell–endothelial cell adhesion.10,11 The mechanism(s) underlying this PS-mediated adhesion process is not well defined. Interaction of PS with immobilized subendothelial matrix thrombospondin has been documented.10 In addition, soluble thrombospondin-mediated adhesion of PS-positive erythrocytes to endothelium can occur via the constitutively expressed endothelial vitronectin receptor (VnR).10 Whether PS–related erythrocyte adhesion to endothelium can occur in the absence of plasma ligands is not known. In the present study, we explore this possibility, and hypothesize that endothelial cells express novel adhesion receptor(s) that can interact directly with PS-positive erythrocytes in the absence of plasma ligands. One such candidate is a receptor that recognizes cell surface–expressed membrane–associated phosphatidylserine, referred hitherto as the phosphatidylserine receptor or PSR, originally described by Fadok et al on the surface of activated macrophages that recognizes and phagocytoses PS–positive apoptotic cells.12 In the present study, we explore whether microvascular endothelial cells express this novel PS receptor. We demonstrate that both PSR transcript and protein are expressed in human microendothelial cells under basal conditions, and that expression is up-regulated following cell activation with various physiologic agonists. In further in vitro studies, we show that this receptor protein is externalized following endothelial cell activation, and that PSR is involved in PS-mediated erythrocyte adhesion to activated endothelium.

Methods

Materials

For enzyme-linked immunosorbent assay (ELISA), flow cytometric analyses, Western blots, and adhesion-blocking studies, monoclonal and polyclonal antibodies against human antigens and isotope–matched negative control antibodies were obtained from Cascade BioScience (Winchester, MA), Immunotech (Beckman-Coulter, Miami, FL), R&D Systems (Minneapolis, MN), BD Biosciences (San Diego, CA), Chemicon International (Temecula, CA), Serotec (Oxford, United Kingdom), Bio-Rad Laboratories (Hercules, CA), Jackson Immunoresearch Laboratories (West Grove, PA), or Sigma Chemical (St Louis, MO). These reagents included either pure or conjugated mouse monoclonal antibodies against PSR (clone 217), CD51 (α-chain of the vimentin receptor, clone AMF7), CD106 (VCAM-1, clones 1G11, 51-10C9, and BBIG-V1), CD36 (the thrombospondin receptor, clone PA6.152), CD49d (α-chain of the VLA-4, clone HP2.1), CD62P (P-selectin, clones CLB-Thromb/6, AK-6, and 9E1), CD54 (ICAM-1, clones 54H10 and BBIG-H1), CD47 (integrin–associated protein or IAP, clone BRIC126), CD239 (BCAM/LU, clone BRIC221), CD144...
Preparation of liposomes
In brief, washed erythrocytes (10% hematocrit in buffer-A [10 mM HEPES in calcium- and magnesium-free Hanks balanced salt solution [CMF-HBSS], pH 7.4] containing 2.5 mM CaCl\(_2\)) were incubated for 1 hour with 2.5 \(\mu\)M of the appropriate monoclonal antibody also were used in representative flow cytometry and markers by flow cytometry. Adhesion assays were conducted in the absence of plasma and soluble ligands. Radiolabeled erythrocytes containing 15% PS-positive cells were evaluated for their adhesive potential using HLMECs. To assess direct interaction of PS with endothelial adhesion receptor(s), adhesion assays were performed using red cells from 9 individuals with HbSS disease, whose red cells by flow cytometry demonstrated either low or relatively high percentage of PS positivity (mean \(\pm\) SD: 1.0% vs 7.0% \(\pm\) 2.8%, respectively). All adhesion experiments were assayed in triplicate with an intra-assay variability of less than 4%.

An analysis of endothelial cell PS mRNA
Steady-state PS mRNA levels were evaluated using reverse-transcriptase–polymerase chain reaction (RT-PCR) analysis. Following incubation of endothelial cells for various times in the presence or absence of the desired agonist, total RNA was isolated using RNAqueous-4PCR kit (Ambion, Austin, TX), and 2 \(\mu\)g total RNA was reverse transcribed using SuperScript-II reverse transcriptase (Invitrogen). The RT product then was amplified using Taq DNA polymerase (Qiagen, Valencia, CA) and 0.8 \(\mu\)M PSR-specific primers. The PSR primers included 5'-CCA-GAA-GTT-GTG-TGG-TGA-GGA-3' (forward, nucleotides 403 through 426) and 5'-ACT-ATG-ATG-TCC-CTG-GGA-GTG-3' (reverse, nucleotides 774 through 751), which yielded a PCR-product of 372 bp. The transcript region selected for our RT-PCR analysis was similar to that previously described for PSR mRNA in brain and spleen from rat and mouse. cDNA for \(\beta\)-actin, a constitutively expressed transcript, was coamplified as an endogenous control for quantitation of PSR mRNA. The \(\beta\)-actin–specific primers (0.0375 \(\mu\)M) used were 5'-ACG-TTG-CTC-AGG-CTG-TGC-GTT-3' (forward, nucleotides 861 through 883) and 5'-ACT-ATG-ATG-TCC-CTG-GGA-GTG-3' (reverse, nucleotides 1125 through 1102) yielding a PCR-product of 372 bp. Both PSR and \(\beta\)-actin primers were selected using the PrimerQuest Software (Integrated DNA Technologies, Coralville, IA) and custom synthesized by Invitrogen. PCR-products were resolved on a 1% agarose gel containing 0.4 \(\mu\)g/mL ethidium bromide and analyzed using a Bio-Rad Gel Doc System. The relative ratio of test to endogenous was determined for each treatment, and expressed as a ratio. For sequence analysis, the amplified PCR fragment from the endothelial PSR transcript was purified using Qiagen Gel Extraction kit and sequenced on an ABI PRISM 310. A 372-bp PCR product containing the 3'-end of the human PSR cDNA was obtained using the following primers: 5'-ACT-ATG-ATG-TCC-CTG-GGA-GTG-3' (reverse, nucleotides 774 through 751), which yielded a PCR-product of 372 bp. The transcript region selected for our RT-PCR analysis was similar to that previously described for PSR mRNA in brain and spleen from rat and mouse. cDNA for \(\beta\)-actin, a constitutively expressed transcript, was coamplified as an endogenous control for quantitation of PSR mRNA. The \(\beta\)-actin–specific primers (0.0375 \(\mu\)M) used were 5'-ACG-TTG-CTC-AGG-CTG-TGC-GTT-3' (forward, nucleotides 861 through 883) and 5'-ACT-ATG-ATG-TCC-CTG-GGA-GTG-3' (reverse, nucleotides 1125 through 1102) yielding a PCR-product of 372 bp. Both PSR and \(\beta\)-actin primers were selected using the PrimerQuest Software (Integrated DNA Technologies, Coralville, IA) and custom synthesized by Invitrogen. PCR-products were resolved on a 1% agarose gel containing 0.4 \(\mu\)g/mL ethidium bromide and analyzed using a Bio-Rad Gel Doc System. The relative ratio of test to endogenous was determined for each treatment, and expressed as a ratio. For sequence analysis, the amplified PCR fragment from the endothelial PSR transcript was purified using Qiagen Gel Extraction kit and sequenced on an ABI PRISM 310.
PRISM Model 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA), and the sequence was matched with published PSR mRNA.

Analysis of endothelial PSR protein

PSR protein levels in endothelial cells were evaluated using a variety of methods including Western blotting of total cellular proteins. Cell surface expression for PSR used 2 complementary methods, that is, flow cytometry–based (cell suspension) and fluorescence-based (intact cell monolayer) ELISA.

Analysis of PSR protein by Western blotting

Following incubation of endothelial cells for various times in the presence or absence of the desired agonist, total cellular proteins were extracted with Laemml sample buffer. Total proteins (20 μg) were denatured in sample buffer, resolved using 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes. Membranes were blocked with 5% milk protein in phosphate-buffered saline containing 0.1% Tween-20, pH 7.4 (Tween-PBS), and probed sequentially with a rabbit polyclonal antibody against PSR (1:2000 dilution) and HRP-conjugated goat anti–rabbit IgG (1:10 000 dilution) diluted in Tween-PBS containing milk protein. After washing in Tween-PBS, immunoreactive proteins were detected using a PerkinElmer ECL kit, images scanned, and protein bands quantitated. Membranes were stripped and reprobed for the constitutively expressed cytoskeletal protein β-tubulin, as an endogenous control (to correct for loading differences).

Analysis of cell-surface expression of PSR protein by flow cytometry

PSR protein expression on endothelial cells was evaluated by flow cytometry following exposure of monolayers to the desired agonist for 6 hours. Endothelial cells were harvested by incubating washed monolayers with 5 mM EDTA in CMF-HBSS. One million cells (suspension in 100 μL buffer-A containing 2.5 mM CaCl2 and 1% BSA) were incubated with anti-PSR (2 μg) or an isotype-matched negative control antibody for 30 minutes, an additional 30 minutes with appropriate secondary antibody (1 μg Cy3-labeled goat anti–mouse IgM or FITC-labeled goat anti–rabbit IgG) in the dark at room temperature, and analyzed in a FACScan Flow Cytometer (BD Immunocytometry Systems, San Jose, CA) at a flow rate of 200 to 500 cells/second. Data from 10 000 events were collected and analyzed. Other endothelial adhesion receptors known to interact with red cells including VCAM-1, CD36, VnR, P-selectin, and ICAM-1 also were evaluated.

Analysis of cell-surface expression of PSR protein by fluorescence ELISA

PSR protein expression on intact HLMEC monolayers was evaluated using an ELISA-based assay similar to that previously described for other endothelial adhesion receptors.19 In brief, following exposure to desired agonist for 6 hours, endothelial monolayers were incubated for 90 minutes with a mouse monoclonal antibody against PSR (10 μg/mL, 200 μL/well), an additional 60 minutes with a goat anti–mouse IgM conjugated with alkaline phosphatase (200 μL/well, 1 to 50 dilution), and finally for 15 minutes with the phosphatase substrate Attophos (Promega, Madison, WI). The reaction was terminated by addition of EDTA and product measured fluorometrically (MilliPore Cytoflour, Model 2350; Millipore, Bedford, MA) with excitation and emission wavelengths set at 450 nm and 580 nm, respectively. All conditions were assayed in triplicate, with an intra-assay variability of less than 4%. Background fluorescence was measured with cells subjected to identical treatment in the presence of an isotype-matched negative control antibody. In parallel experiments, VCAM-1, CD36, and VnR, with an appropriate isotype-matched negative control antibody, were evaluated to complement flow cytometric analyses. Surface expression of PSR and other adhesion receptors also were evaluated using HRCECs to complement data from human lung cells.

Statistical analysis

Statistical evaluation was performed using Sigmastat Statistical Package (Jandel Scientific, San Rafael, CA). All results are presented as means (± SD). Multiple group comparison was done using either one-way ANOVA (for data with normal distribution) or the Kruskal-Wallis test (for data with nonnormal distribution). If the P value for this overall comparison was statistically significant at P < .05, then group-wise comparison was performed using Dunn test or Dunn test. The unpaired or paired Student t test, or the Mann-Whitney rank sum test on the medians, if the data showed nonnormal distribution, was used to compare statistical significance between 2 groups.

Results

Adhesion of PS-positive erythrocytes to lung microendothelial cells under basal and activated conditions

As depicted in Figure 1A, adhesion of PS-positive erythrocytes to lung microendothelial cells increased by approximately 2.5-fold compared with PS-negative cells (n = 10, P < .01). This adhesion
was further enhanced by 2.5- to 8-fold following activation of endothelial cells with agonists such as IL-1α, TNF-α, LPS, or hypoxia (n = 3 to 12, P < .05 to P < .001). Cell activation had no significant effect on PS-negative erythrocyte adhesion to endothelial cells. As shown in Figure 1B, to assess specificity of PS-mediated adhesion, we evaluated the effects of annexin-V (used to cover surface PS), PS liposomes and serine-L-phosphate (competitors for PS binding), PC liposomes (control for PS liposomes), and serine-D-phosphate (control for serine-L-phosphate) on adhesion. Results demonstrate that preincubation of red cells with annexin-V or pretreatment of red cells and endothelial cells with PS liposomes inhibited adhesion of PS-positive erythrocytes to activated endothelial cells by 52% and 57%, respectively (P < .01), while PC liposomes had no effect. While pretreatment of PS-positive red cells and endothelial cells with serine-L-phosphate inhibited erythrocyte adhesion to activated endothelial cells by 52% (P < .01), serine-D-phosphate had no effect. Adhesion of PS-positive red cells to unactivated endothelial cells was also inhibited by 31% and 28% with annexin-V and PS liposomes, respectively (P < .05). None of the PS modulators tested had any significant effect on PS-negative erythrocyte adhesion to activated endothelial cells. These studies demonstrate that the interaction between erythrocytes and endothelial cells is PS specific, and suggest that novel adhesion receptors recognizing PS-positive erythrocytes are expressed on activated endothelium.

Lung microendothelial cells express PSR mRNA and protein

We next assessed whether PSR (previously reported to be expressed on activated macrophages) was present in endothelial cells. Using RT-PCR, we demonstrate the presence of PSR mRNA in total cellular RNA from unstimulated control human lung microvascular endothelial cells (Figure 2B lane 1). Identity of the PCR product was confirmed by sequence analysis, which showed 100% homology to this region in the published PSR mRNA sequence. Treatment of endothelial cells with IL-1α (10 ng/mL) up-regulated PSR mRNA in a time-dependent manner with maximal levels (~3-fold increase) noted at 4 hours following cell activation (Figure 2A,B lane 2, 2C). Activation of endothelial cells with TNF-α (10 ng/mL) and heme (100 μM) also up-regulated PSR mRNA by 138% and 100%, respectively (Figure 2B lanes 3, 4, 2C). We next evaluated whether PSR mRNA was translated to PSR protein in endothelial cells by immunoblotting total cellular proteins with a PSR-specific antibody. Endothelial PSR protein levels mirrored steady-state mRNA levels. Basal PSR protein expression that was detected in unactivated control endothelial cells (Figure 3B lane 1) was up-regulated in a time-dependent manner following activation with IL-1α with maximal stimulation of approximately 175% noted over baseline at 6 hours (Figure 3A,B lane 2, 3C). Other activators including TNF-α and heme, which up-regulated PSR mRNA in endothelial cells, also enhanced PSR protein expression in these cells by 89% and 58%, respectively, over baseline (Figure 3B lanes 3, 4, 3C). These studies demonstrate that lung microendothelial cells express both PSR transcript and protein constitutively, and that their expression is up-regulated by cell activation.
Cell-surface expression of PSR protein on lung microendothelial cells

While immunoblotting of total cellular proteins demonstrated the presence of PSR protein in endothelial cells, these experiments did not reveal whether this receptor protein was present on the cell surface. Using complementary flow cytometric- and ELISA-based assays, with IL-1α and TNF-α as agonists, and both monoclonal (Cascade anti-PSR and Henson antibody) and polyclonal (Sigma Chemical) anti-PSR, we next explored whether PSR protein was expressed on the endothelial surface. Results presented in Figure 4Bi demonstrate that while endothelial cells were minimally positive for PSR in the unactivated state (3.3% cells), significant numbers of cells acquired PSR positivity following activation with IL-1α or TNF-α (∼20%-30% cells, Figure 4Bii,iii). Similar PSR expression profiles also were observed when the second mouse monoclonal anti-PSR antibody (Henson antibody, Figure 4Ci-iii) and a PSR polyclonal antibody (Figure 4Di-iii) were used in flow cytometric analysis. These findings also were confirmed using a complementary ELISA-based assay using intact cell monolayer activated with IL-1α or TNF-α (∼3-fold induction with both modulators, Figure 5A). The agonists LPS and hypoxia also induced cell surface PSR expression by 1.6- and 4-fold, respectively (Figure 5A). Representative adhesion markers that are constitutively expressed (VnR), induced (VCAM-1), and up-regulated (CD36) in endothelial cells also were evaluated concomitantly in both flow cytometric- and ELISA-based analyses for comparison with the PSR expression profile. As shown in Table 1 and Figure 5A, no significant changes in the constitutively expressing VnR were noted in response to activation by the cytokines IL-1α or TNF-α. While both cytokines induced the expression of VCAM-1 on the lung microendothelium, no significant changes in CD36 expression were noted at the concentration of agonists used in both flow cytometric- and ELISA-based (Table 1) and ELISA-based (Figure 5A) assays. A similar adhesion molecule expression profile was noted in intact human retinal capillary endothelial cell monolayers. These studies demonstrate that while PSR is minimally expressed constitutively on the cell surface, its expression is

Figure 4. Surface expression of PSR protein on human lung microendothelial cells: analysis by flow cytometry. Following incubation of endothelial cells for 6 hours in the absence (left column) or presence of IL-1α (10 ng/mL, middle column) or TNF-α (10 ng/mL, right column), cells were harvested, labeled with desired test antibody or an equivalent amount of an isotype-matched negative control, and analyzed by flow cytometry as detailed. Endothelial cells labeled with mouse monoclonal antibody against PSR from Cascade Bioscience (Bi-iii), Dr Henson’s laboratories (Ci-iii), and a rabbit polyclonal antibody against PSR from Sigma Chemical (Di-iii) are shown. Results presented are from a representative experiment repeated 4 to 6 times with similar results. Endothelial cells labeled with appropriate isotype-matched negative control antibodies are shown in panels Ai-iii. The red and blue lines are the negative histogram profiles for the rabbit polyclonal and mouse monoclonal antibodies, respectively. Markers M1 and M2 are the positive histogram regions for the anti-PSR monoclonal and polyclonal antibodies that were set up with endothelial cells labeled with appropriate isotype-matched negative control antibodies. Percentage marker-positive cells is shown in each panel. HT1080 cells analyzed concomitantly demonstrated 71% to 79% positivity with all 3 antibodies.
Detailed. Values presented are the means (± SD) from 4 experiments. MCF, mean cell count.

**A**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Unstimulated endothelial cell control</th>
<th>IL-1α–activated endothelial cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD51 Positivity</td>
<td>87 ± 9%</td>
<td>90 ± 8%</td>
</tr>
<tr>
<td>MCF</td>
<td>340 ± 28</td>
<td>389 ± 3</td>
</tr>
<tr>
<td>PSR Positivity</td>
<td>5 ± 0.5%</td>
<td>26 ± 3%</td>
</tr>
<tr>
<td>MCF</td>
<td>38 ± 3</td>
<td>175 ± 21</td>
</tr>
<tr>
<td>CD36 Positivity</td>
<td>33 ± 18%</td>
<td>30 ± 16%</td>
</tr>
<tr>
<td>MCF</td>
<td>116 ± 29</td>
<td>115 ± 43</td>
</tr>
<tr>
<td>ICAM-1 Positivity</td>
<td>38 ± 7</td>
<td>92 ± 3%</td>
</tr>
<tr>
<td>MCF</td>
<td>268 ± 33</td>
<td>607 ± 9</td>
</tr>
<tr>
<td>VCAM-1 Positivity</td>
<td>7 ± 3%</td>
<td>53 ± 16%</td>
</tr>
<tr>
<td>MCF</td>
<td>45 ± 8</td>
<td>322 ± 97</td>
</tr>
</tbody>
</table>

**B**

Besides being characterized to be positive for acetylated LDL receptor, Factor VIII-related antigen and CD31 by the manufacturer, the lung endothelial cells used in the study were identified by flow cytometric analyses to be 90 to 98% positive for constitutively expressed antigens including CD146, and CD144 (two endothelial-specific antigens). Following incubation of endothelial cells for 6 hours in the absence, or presence of IL-1α (10 ng/mL), cells were harvested, labeled with desired test antibody or an equivalent control antibodies (IgG or IgM) had no significant effects on either

**Table 1. Adhesion molecules expressed on human lung microvascular endothelial cells**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Unstimulated endothelial cell control</th>
<th>IL-1α–activated endothelial cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD51 Positivity</td>
<td>87 ± 9%</td>
<td>90 ± 8%</td>
</tr>
<tr>
<td>MCF</td>
<td>340 ± 28</td>
<td>389 ± 3</td>
</tr>
<tr>
<td>PSR Positivity</td>
<td>5 ± 0.5%</td>
<td>26 ± 3%</td>
</tr>
<tr>
<td>MCF</td>
<td>38 ± 3</td>
<td>175 ± 21</td>
</tr>
<tr>
<td>CD36 Positivity</td>
<td>33 ± 18%</td>
<td>30 ± 16%</td>
</tr>
<tr>
<td>MCF</td>
<td>116 ± 29</td>
<td>115 ± 43</td>
</tr>
<tr>
<td>ICAM-1 Positivity</td>
<td>38 ± 7</td>
<td>92 ± 3%</td>
</tr>
<tr>
<td>MCF</td>
<td>268 ± 33</td>
<td>607 ± 9</td>
</tr>
<tr>
<td>VCAM-1 Positivity</td>
<td>7 ± 3%</td>
<td>53 ± 16%</td>
</tr>
<tr>
<td>MCF</td>
<td>45 ± 8</td>
<td>322 ± 97</td>
</tr>
</tbody>
</table>

*P-selectin Positivity Not detected Not detected

*P-selectin expression was undetectable under the experimental conditions described, P-selectin-positivity was noted on endothelial cells activated with A23187 for 30-minutes (see the results section for details). Multiple monoclonal antibodies were employed to identify the expression of ICAM-1 (clones 84H10, and BBIG-I1), VCAM-1 (clones 1G11, 51-10C9, and BBIG-V1), and P-selectin (clones CLB-Thromb/6, and AK-6). Similar expression profiles of adhesion markers were noted on the endothelial surface with different monoclonal antibodies. Results shown for ICAM-1, and VCAM-1 were obtained with clones 84H10, and 51-10C9, respectively.

**Figure 5.** Surface expression of PSR protein and other adhesion markers on human microendothelial cells: analysis by fluorescence ELISA. (A) Expression of PSR protein on intact HMLECs. Human lung microendothelial cells were subjected to activation for 6 hours with IL-1α (10 ng/mL), TNF-α (10 ng/mL), or LPS (100 ng/mL), or for 24 hours with hypoxia, and then assessed for surface PSR using an ELISA-based assay. Expression profiles of VCAM-1, CD36, and the vitronectin receptor (VnR) in response to endothelial activation are also shown. Values presented are the mean plus or minus SD from 4 to 6 experiments. (B) Expression of PSR protein on intact HRCECs. Human retinal capillary endothelial cells were subjected to activation for 6 hours with IL-1α (10 ng/mL), TNF-α (10 ng/mL), or LPS (100 ng/mL), or for 24 hours with hypoxia, and then assessed for surface PSR using an ELISA-based assay. Expression profiles of VCAM-1, CD36, and the vitronectin receptor (VnR) in response to endothelial activation are also shown. Values presented are the mean plus or minus SD from 3 experiments.

**PSR supports adhesion of PS-positive erythrocytes to lung microendothelial cells**

To assess the potential linkage between PSR expression and functional adhesion, we performed concomitant adhesion assays in the presence of PSR-specific antibodies initially using ionophore-activated HbAA red cells. As depicted in Figure 6, while no significant changes in adhesion to unactivated endothelium was noted, anti-PSR inhibited PS-positive erythrocyte adhesion to activated endothelium by 45% (n = 4, P < .01). Similar differential inhibitory effects were also observed with the Henson antibody and the polyclonal anti-PSR antibody. Since multiple endothelial receptors support erythrocyte adhesion, it became necessary to identify the adhesion molecules expressed on the surface of the cells that were integral to these experiments (eg, IL-1α–stimulated lung microvascular endothelial cells and the A23187-treated control HbAA erythrocytes). As depicted in Table 1, IL-1α–stimulated lung microendothelial cells expressed all adhesion receptors known to interact with red cells with the exception of P-selectin (CD62P). As shown in Table 2, among the red cell adhesion markers evaluated, only PS showed both qualitative and quantitative differences on the ionophore-treated HbAA red cell surface compared with untreated control erythrocytes. In adhesion experiments (n = 4-6), preincubation of endothelial cells with anti-VnR, anti–CD36, anti–VCAM-1, anti–ICAM-1, or isotype-matched negative control antibodies (IgG or IgM) had no significant effects on either
basal or IL-1α–stimulated adhesion. While CD62P expression was undetectable under the experimental conditions described (ie, IL-1α activation), P-selectin positivity was noted following endothelial activation with A23187 (160 ± 40 vs 400 ± 180 fluorescence units, n = 4, by ELISA with unstimulated and A23187 treated, respectively). To complete these analyses, we therefore pretreated A23187-activated endothelial cells with anti-CD62P, and demonstrate that this antibody had no significant effect on PS-mediated erythrocyte adhesion (Figure 6). In final adhesion experiments, we evaluated erythrocytes from patients with sickle cell disease (HbSS genotype) with various levels of PS positivity ranging from 0.3% to 11% dividing them into 2 experimental groups including low versus high PS-positive HbSS erythrocytes (1.0% ± 0.8% vs 7.0% ± 2.8% positivity, P < .02, Table 2) as we have done in previous studies.5 As shown in Figure 7, while the anti-PSR polyclonal antibody had no significant effect on either unstimulated or IL-1α–stimulated adhesion of low-percentage PS-positive HbSS erythrocytes to microvascular endothelium (panel A), a significant inhibition in adhesion of HbSS erythrocytes containing high-percentage PS-positive cells was noted to IL-1α–activated microendothelial cells (65% ± 32% inhibition of agonist-induced adhesion, P = .05, panel B). These findings taken together demonstrate that PSR supports PS-mediated erythrocyte adhesion to IL-1α–activated endothelium in the absence of serum or plasma-associated adhesinogenic ligands and that the adhesion occurs with PS-expressing cells generated under both artificial and pathophysiologic circumstances.

**Discussion**

Our results demonstrate that human lung microendothelial cells express both mRNA and protein for PS receptor under basal conditions, and that expression of this receptor is up-regulated following endothelial activation. While minimally expressed on the cell surface under basal conditions, surface expression of PSR is up-regulated following cell activation by a variety of pathophysiologic agonists including IL-1α, TNF-α, LPS, heme, and hypoxia. In additional experiments, we demonstrate that PSR expressed on the cell surface is functional, supporting the direct adhesion of PS-positive erythrocytes to activated microendothelium.

PSR, originally described by Fadok et al, is expressed on the surface of activated macrophages,12 and also present constitutively on the surface of fibroblasts and epithelial cells,12 with recent studies also documenting nuclear localization in fibroblasts.24 It is not expressed by the circulating cellular elements of blood including neutrophils, lymphocytes, monocytes, and erythrocytes.12 PSR, expressed on both phagocytes (macrophages) and nonphagocytes (fibroblasts and epithelial cells), appears to mediate phagocytic recognition and removal of PS-expressing apoptotic cells,12,20,21,25 although there remains some controversial evidence regarding this function. PSR plays an essential role in development and differentiation of multiple organs during embryogenesis. Using PSR knockout mouse models, recent studies have demonstrated that PSR disruption leads to growth retardation and defects in embryonic organogenesis and perinatal lethality presumed to be due to ineffective apoptotic cell phagocytosis, although this has

![Image](https://example.com/image.png)

**Figure 6.** Effects of antibodies against PSR and other endothelial adhesion markers on PS-positive erythrocyte adhesion to human lung microendothelial cells. Following incubation of endothelial cells for 6 hours in the presence or absence of IL-1α (10 ng/mL), cell monolayers were pretreated with antibodies against desired adhesion molecule at 40 μg/mL, or an equivalent amount of an isotype-matched negative control immunoglobulin (IgG or IgM) for 45 minutes. The monolayers were then tested for their adhesive potential using PS-positive red cells with 15% PS positivity prepared by treating control erythrocytes with A23187. These adhesion assays were performed using red cells at 10% hematocrit in the absence of plasma and plasma-associated soluble adhesion ligands. Results presented are the mean (± SD) from 3 to 7 experiments. Adhesion of test red cells to test endothelium was presented as fold change compared with adhesion of PS-negative red cells to unactivated endothelial cells. *Values significantly different from the respective medium control or the IgM control at P < .01. Please note that to test CD62P or P-selectin–mediated adhesion, endothelial cells were subjected to activation with A23187 for 30 minutes, pretreated with anti-CD62P for 45 minutes, and then assessed for their adhesinogenic potential with PS-positive erythrocytes (see legend to Table 1 and “Results” for additional details).

**Table 2.** Adhesion molecules expressed on control erythrocytes made artificially PS-positive and on erythrocytes from patients with sickle cell disease

<table>
<thead>
<tr>
<th>Marker</th>
<th>Erythrocytes from control donors</th>
<th>Erythrocytes from patients with sickle cell disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Untreated (n = 4)</td>
<td>*A23187-treated erythrocytes diluted with untreated RBCs (n = 4)</td>
</tr>
<tr>
<td>CD36 Positivity</td>
<td>Not present</td>
<td>Not present</td>
</tr>
<tr>
<td>VLA4 Positivity</td>
<td>Not present</td>
<td>Not present</td>
</tr>
<tr>
<td>PS Positivity</td>
<td>&lt; 0.3%</td>
<td>15%</td>
</tr>
<tr>
<td>CD47 (IAP)</td>
<td>100%: 629 ± 15</td>
<td>100%: 630 ± 32</td>
</tr>
<tr>
<td>CD239 (BCAM/LU)</td>
<td>23 ± 16%, 305 ± 47</td>
<td>20 ± 13%, 300 ± 32</td>
</tr>
</tbody>
</table>

Cell-surface PS and other potential erythrocyte adhesion markers were evaluated using 2-color flow cytometry and employing anti-glycopherin A as a marker for red cells. Values presented are the mean (± SD). Mean cell fluorescence (MCF) is a measure of receptor density per cell. Changes (positivity or MCF) noted with CD47 or CD239 between the control and A23187-treated erythrocyte were not significantly different from each other. The “low” PS sickle cell group is compared with the “high” PS sickle cell group to demonstrate that the adhesion marker differences between these two HbSS groups was confined to significant differences in PS positivity.

IAP indicates integrin associated protein; and BCAM/LU, basal cell adhesion molecule/Lutheran protein.

†PS-positive red cells were prepared by treating control HbAA erythrocytes with A23187 and diluted with untreated red cells to obtain a cell suspension containing 15% PS positivity.

††Erythrocytes from patients with sickle cell disease (HbSS genotype) were divided into 2 experimental groups including low PS and high PS groups based on percent PS positivity as in our previous study.5

†††P < .02 compared to low PS group.
PSR has been recently questioned. PSR appears to be a glycosylated protein with an apparent molecular size of 70 kDa and contains a type II transmembrane domain, a potential intracellular tyrosine phosphorylation site, and an extracellular domain containing runs of serines (which could be involved in protein O-glycosylation) and runs of basic amino acids lysine and arginine that could provide potential binding sites for the anionic phospholipid PS. While recent studies have also identified multiple nuclear localization signals in the PSR sequence, a physiologic role for nuclear PSR has yet to be elucidated. In the present study, we found that the endothelial PSR migrated as a protein with a molecular size of approximately 70 kDa. We observed both basal and up-regulated expression of endothelial PSR, surface expression was noted mainly on activated endothelium using both polyclonal and monoclonal antibodies. A recent study also documented constitutive expression of PSR in a macrovascular endothelium, and showed that PSR mediated tethering of apoptotic Jurkat cells to endothelial cells. In the present study, we have characterized PSR expression at both the mRNA and protein level in pathologically relevant human pulmonary microvascular endothelium. We have also used complementary methods (Western blotting, flow cytometry, and ELISA assays) and also both polyclonal and monoclonal antibodies to characterize PSR protein. In addition, we have demonstrated that endothelial activation by IL-1α, TNF-α, LPS, heme, and hypoxia up-regulated surface expression of PSR.

The findings that surface PSR expression occurred mainly on the activated endothelium and that pretreatment of activated endothelial cells with anti-PSR antibody inhibited adhesion of PS-positive erythrocytes in the absence of plasma or soluble plasma adhesion ligands demonstrate that endothelial PSR supports PS-mediated direct interaction of erythrocytes to activated microendothelium. PSR is very unlikely to be involved under basal unstimulated conditions since PSR does not appear to be constitutively expressed on the cell surface, with the antibody-blocking experiments corroborating the null effect. These results also implicate at least one more additional non-PSR-associated pathway by which PS-positive cells interact directly with activated endothelial cells in the absence of plasma ligands. Existence of a non-PSR-mediated adhesion pathway was also suggested by the findings that PS-positive erythrocytes interacted with unactivated control endothelial cells and that this basal adhesion was not affected by pretreatment of endothelial cells with anti-PSR prior to adhesion. Since previous studies demonstrated that erythrocytes from pathologic milieu interact, either directly or indirectly via plasma ligands, with CD36, VCAM-1, ICAM-1, and P-selectin (also reviewed in references Frenette; Parise and Telen; Stuart and Nagel), and since human lung microendothelial cells express these adhesion molecules either constitutively or following activation (Table 1), we explored the possible involvement of these receptors in the direct adhesion of PS-positive erythrocytes to human lung microendothelial cells. Antibody-blocking studies (Figure 6) suggested that these latter endothelial receptors are not involved. In our adhesion experiments, we initially used PS-positive erythrocytes prepared by activating control HbAA erythrocytes with the calcium ionophore A23187. Use of HbAA control cells obviated the involvement of the adhesion markers VLA4 and CD36 that are also expressed with PS on a subset of young erythrocytes (stress reticulocytes) in patients with hemolytic anemias including sickle cell disease. While other adhesion molecules including CD47 and B-CAM/LU are also present on control erythrocytes, levels (both receptor positivity and density) of these receptors did not change following activation of red cells with the ionophore. Erythrocyte-endothelial interactions described in this study appeared to be mediated, in part, via erythrocyte PS, since pretreatment of PS-positive erythrocytes with annexin-V, or preincubation of erythrocytes and/or endothelial cells with PS liposomes, or serine-L-phosphate inhibited adhesion (Figure 1B). In contrast, PC liposomes and serine-t-phosphate had no effect on this process.

Erythrocytes from patients with several hemolytic anemias including sickle cell disease (SCD), thalassemia, malaria, and chronic renal failure are positive for PS with levels ranging from 0.5% to more than 10%, and exhibit increased adhesiveness to endothelium, with our previous published data documenting a significant positive correlation between percentage sickle red cell PS positivity and adhesion where enhanced erythrocyte-endothelial adhesion was noted in the high PS-positive group (mean percentage positivity at 5.6%). In the present in vitro study, we also note that PS-mediated erythrocyte adhesion occurs at similar levels of PS positivity (mean percentage positivity at 7%), and that a polyclonal antibody against PSR significantly inhibited this adhesion (Figure 7). Erythrocyte adhesion to endothelium correlates with disease severity in patients with SCD, and is a major etiologic factor in the pathogenesis of the vaso-occlusive or painful crisis with long-term effects including chronic organ dysfunction leading to increased morbidity and mortality. Cell-surface expression of PSR occurred on the microendothelium following activation of cells in vitro with agonists such as IL-1α, TNF-α, heme, and hypoxia, agonists that are all pathologically relevant in patients with sickle cell disease. Evidence also suggests both chronic and acute endothelial activation in these patients as documented by elevated levels of soluble VCAM-1, E-selectin, and...
ICAM-1 by many investigators including results from our laboratories. It is not known whether in vivo PSR expression occurs under the influence of agonists that caused PSR expression under the in vitro conditions described here, and whether red cell PS-endothelial PSR adhesion occurs in the microvasculature in such pathologic conditions as SCD and malarial infection where such adhesion could influence disease pathology. Further studies are required in appropriate animal models such as the transgenic sickle mouse to delineate further the relevance of this novel endothelial receptor in the process of in vivo cell-cell adhesion.

An interesting observation made by several investigators related to PSR is its involvement in mediating anti-inflammatory responses in numerous experimental models. Ligation of PSR with apoptotic cells through PS or PS liposomes up-regulated the production of anti-inflammatory cytokines transforming growth factor-β and IL-10 concomitant with the down-regulation of the proinflammatory cytokines TNF-α and IL-1 in mouse macrophages and epithelial cells. Endothelial cells appear to synthesize and release many proinflammatory and anti-inflammatory cytokines including IL-1, IL-6, IL-8, and ET-1. Thus, an additional role for endothelial PSR in the microvasculature could be the modulation of the inflammatory phenotype especially in disease states where the combination of adhesion and inflammation are a particularly potent mix in relation to vascular and organ dysfunction.

In summary, we demonstrated the presence of a receptor for phosphatidylserine, PSR, on the surface of human microendothelial cells using both antigen expression and mRNA analysis. While PSR is not constitutively expressed, its expression can be induced on the surface of microendothelium by relevant agonists such as LPS, cytokines, hypoxia, and heme. PSR is involved in mediating direct interaction of PS-positive erythrocytes with microendothelial cells. The in vivo significance of these interactions requires further studies in relevant disease models.

Acknowledgments

B.N.Y.S. thanks Dr Marie Stuart for her support throughout the study, critical evaluation of the study design, and review of the paper. We thank Dr Saul Sury for his evaluation of the paper, Dr Peter Henson for the kind gift of anti-PSR antibody and his review of our paper, Mrs Surekha Kulkarni and Dottie Shields for their assistance in data acquisition in some flow cytometry-related experiments, and Mrs Jie Zhang for assistance in setting up Western analysis. The authors also thank Dr Carlton Dampier and the staff members of the division of Hematology, St Christopher’s Hospital for Children, Drexel University, for their cooperation in obtaining blood samples for these studies. This work was supported by grants U54 HL70585 and R01 HL73944 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.

Authorship

Contribution: B.N.Y.S. designed the study, supervised and performed the experiments, performed statistical analysis, critically evaluated and interpreted the data, and wrote the paper. S.G.B. performed molecular biology experiments.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: B. N. Yamaja Setty, Thomas Jefferson University, Department of Pediatrics, Medical College Bldg, Suite 727, 1025 Walnut St, Philadelphia, PA 19107; e-mail: yamaja.setty@jefferson.edu.

References


52. Conran N, Fattori A, Saad ST, Costa FF. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am J Hematol. 2004;76:343-347.


